The BCL6 gene, mapped at the chromosomal band 3q27, encodes a POZ/Zinc ®nger transcription repressor protein. It is frequently activated in Non-Hodgkin's lymphomas (NHL) by translocations with breakpoints clustering in the 5' major breakpoint region (MBR) as well as by mutations in the same region. The translocations lead to BCL6 activation by substitution of promoters of rearranging genes derived from the reciprocal chromosomal partners such as IG. We report the molecular genetic analysis of a novel t(2;3)(q21;q27) translocation subset in NHL comprising three cases without apparent BCL6 involvement in the translocation. Southern blot analysis of tumor DNAs utilizing BCL6 MBR probes revealed no rearrangement in two cases. Two rearranged bands in the third case resulted from a deletion in one allele and a mutation in the other allele. Southern blot analysis of DNA from one of the two tumors without BCL6 rearrangement, using a probe derived from the recently identi®ed alternative breakpoint region (ABR), showed a rearrangement. The ABR is located 200 ± 270 kb telomeric to MBR. Mutations were identi®ed in the previously reported hypermutable region of BCL6 in all three tumors. In one, the mutant allele alone was found to be expressed by RT ± PCR analysis of RNA. These results demonstrate the presence of 3q27 translocation breakpoints at a distance from BCL6 suggesting distant breaks that deregulate the gene or involvement of other genes that may be subject to rearrangement.
Introduction
Chromosomal translocations aecting band 3q27 have been noted to occur frequently in diuse large cell lymphoma (DLCL) and other subsets of nonHodgkin's lymphoma (NHL) (Ot et al., 1989; Bastard et al., 1992) . By molecular genetic analysis of t(3;14) (q27;q32) translocations, the BCL6 gene was isolated and mapped to 3q27 adjacent to the chromosomal breakpoint (Baron et al., 1993; Kerckaert et al., 1993; Ye et al., 1993a; Miki et al., 1994) . The BCL6 gene encodes a POZ/Zinc ®nger transcription factor which functions as a sequence speci®c transcription repressor Chang et al., 1996; Seyfert 1996; Baron et al., 1997) . The primary function of BCL6 appears to be regulation of germinal center (GC) development and T-cell directed immune response (Dent et al., 1997; Ye et al., 1997) . Activating BCL6 rearrangements have been shown to result from chromosomal translocations with IG or other loci that alter BCL6 expression by promoter substitution, or from point mutations in the 5' regulatory region (Migliazza et al., 1995; Ye et al., 1995; Chen et al., 1998) . The rearrangements cluster in a major breakpoint region (MBR) mapped to the ®rst non-coding exon and 5' of the ®rst intron (Ye et al., 1993b) . More recently, an alternative breakpoint region (ABR) to the MBR was identi®ed in B-cell NHL at 3q27 and shown to be located 200 ± 270 kb in the telomeric direction of BCL6 (Butler et al., 1997) . BCL6 mutations, which have been noted in 73% of DLCLs and 47% of follicular lymphomas (FL), cluster in a *730 bp noncoding region which spans the ®rst exon-intron boundary (Migliazza et al., 1995) . Recent studies also identi®ed recurrent deletions in the MBR region, independent of chromosomal rearrangements (Nakamura et al., 1996; Bernardin et al., 1997) .
We and others have shown that 3q27 promiscuous translocations involve multiple partner chromosomal sites such as 1q21, 2q21, 4q21, 5q13, 11q13, 12q24 and 15q21 (Ye et al 1993a; Wlodarska et al., 1995) . Recently, three genes, TTF, BOB1 and H4, have been identi®ed by cloning the BCL6 breakpoints in tumors with t(3;4)(q27;p11), t(3;11)(q27;q23) and t(3;6) (q27;p21) translocations, respectively (Dallery et al., 1995; Galiegue-Zouitina et al., 1995; Akasaka et al., 1997) . We report here the results of molecular genetic analysis of a novel t(2;3)(q21;q27) subset in NHL, in which the BCL6 gene exhibits deletions and point mutations in the 5' regulatory region; however, the translocation breakpoint is at a distance upstream of the locus.
Results

Southern blot analysis of rearrangements
In an attempt to detect BCL6 rearrangements in the three tumors, Southern blot analysis was performed on available genomic DNA digested with the restriction enzymes BamHI, XbaI, and HindIII using genomic probes spanning the MBR and ABR. No rearrangement was detected with the MBR probes in tumors 1187 and 1562. In the case of tumor 1254, one rearranged BamHI fragment and two rearranged XbaI fragments were detected upon hybridization with the probe pGS4.0 (Figures 1 and 2a) . A genomic library constructed from this tumor was screened with the same probe, which yielded six BCL6 positive clones. Mapping analysis of these clones identi®ed two rearrangement fragments. In one, the rearrangement resulted from a 2.3 kb deletion within a 3.4 kb EcoRI fragment spanning the ®rst exon and the 5' region of the ®rst intron, while the other resulted from a point mutation that generated a new XbaI site in the ®rst exon (Figure 2b ). Both alterations were located in the previously identi®ed hypermutable region (Migliazza et al., 1995) . Further subcloning and sequencing of the rearranged fragments identi®ed additional subtle mutations (Figures 2b and 3) .
In tumor 1562, the ABR probe (XN 1.3) detected rearrangement with two restriction enzymes (Figure 4) . Thus, the t(2;3)(q21;q27) translocation in this case is most likely associated with a chromosomal break occurring within the ABR at 3q27 200 ± 270 kb telomeric to BCL6. No rearrangement was noted in tumor 1187, while DNA for similar analysis was unavailable for tumor 1254. In allele A, a point mutation of G to A generated a new XbaI restriction site (TCTAGA) in exon 1. The hatched box covers the region with all the mutations detected, the frequency of each type of mutation is also shown. In allele B, the dotted line identi®es the deletion. An inversion and another deletion also were noted 3' of this deletion. Pa and Pb denote BCL6 promoters. R, S, and X indicate the restriction enzymes EcoRI, SacI, and XbaI, respectively t(2;3)(q21;q27) translocation in NHL W Chen et al
FISH analysis
FISH analysis was also performed on interphase nuclei from tumors 1254 and 1562 using the PAC-133-MI9 and P1-371-08 and YAC 19G10 ( Figure 4 ). No split signal was detected in 100 interphase nuclei from each tumor following hybridization with the PAC and P1 probes, while the YAC hybridization results were uninformative due to high repeat sequence content. Lymphoma cells suitable for FISH analysis were not available from tumor 1187.
PCR ± SSCP analysis of mutations
Mutation analysis was performed on tumors 1187 and 1562 by PCR ± SSCP of BCL6 sequences¯anking the hypermutable region using previously described primers (Mgliazza et al., 1995) . SSCP variants were observed in the PCR fragments El.11 and El.14, representing the ®rst exon and exon-intron boundary in both tumors ( Figure 5 ).
Identi®cation of the expressed allele in tumor 1254 by RT ± PCR
The biallelic nature of the mutations observed in tumor 1254 prompted us to analyse the expression of the two alleles. For this, RT ± PCR was performed using RNA isolated from a snap-frozen biopsy of the tumor. Since the deletions occurred almost at the beginning of the BCL6 transcript, the 5' anchor primer was adapted for ampli®cation of the CDNA. The ®nal PCR product ampli®ed by the 5' anchor primer and primer 567 at exon 4 yielded * 400 bp fragment on the agarose gel, corresponding to the BCL6 germline fragment ( Figure  6 ). No variant transcript corresponding to allele B with the deletion was detected. The 400 bp PCR fragment was subloned into pGEM-T vector (Promega) and sequenced. The point mutation in allele A that generated a new XbaI site (Figure 2b ) was found in all of the 10 selected cDNA clones. These results suggest that the only expressed BCL6 allele in this tumor was the mutated allele.
Discussion
The majority of B cell NHLs exhibit recurring chromosomal translocations involving the IG genes and several proto-oncogenes. At the molecular genetic level, such translocation analysed in the greatest detail comprise those associated with Burkitt's lymphoma (BL) and FL, wherein the expression of MYC and BCL2 genes, respectively, is deregulated as a result of translocations which juxtapose these genes with one of the IG loci (Dalla-Favera et al., 1982; Taub et al., 1982; Bakhshi et al., 1985) . In contrast, translocations aecting BCL6 are promiscuous and involve multiple gene partners, in addition to the IG genes. More than 17 dierent chromosomal sites have been identi®ed which participate in translocations with 3q27 (Bastard et al., 1992; Ye et al., 1993a; Wlodarska et al., 1995) . We have recently shown that heterologous promoters fused to BCL6 in these translocations lead to its persistent expression beyond its developmentally regulated point of downregulation during B-cell development, leading to lymphomagenesis .
Here we report the molecular genetic analysis of the t(2;3)(q21;q27) translocation subset comprising one case each of FSCL, FMxL, and DLCL. To date, this translocation has been reported in four cases of NHL (Kornblau et al., 1991; Konishi et al., 1990; Bloom®eld et al., 1983; Benitze et al., 1992) , thus identifying a new subset of recurring translocation in NHL. Notably, the t(2;3)(q21;q27) translocation was the only chromosomal abnormality in case 1254.
No BCL6 rearrangements associated with the chromosomal translocation was detected within the MBR or 100 kb 5' of the BCL6 locus in any of the three tumors by Southern blot and/or FISH analysis, suggesting the presence of variant breakpoint(s) at a distance from BCL6. Consistent with this ®nding, in a recent study by us, 50% of NHL with 3q27 chromosomal rearrangements failed to exhibit BCL6-MBR rearrangements . Wlodarska et al. (1995) also were unable to detect a BCL6-MBR rearrangement in a case of NHL with a t(1;3)(q21;q27) translocation by FISH analysis. In one tumor (1562) we localized the 3q27 breakpoint to the recently identi®ed ABR, 200 ± 270 kb telomeric to BCL6. This and other possible distant breakpoints may harbor long range regulatory element(s) capable of deregulating BCL6 expression. Studies of BL translocations have shown that the t(8;14)(q24;q32) translocation breakpoints can be as far as 300 kb A mutation in the exon 1 region that generated a new XbaI restriction site is shown. The sequence shown here represents the antisense strand. Arrow points to the mutation, the solid line on the side indicates the XbaI site. DNA sequence derived from the normal counterpart of the patient 1254 was used as a negative control t(2;3)(q21;q27) translocation in NHL W Chen et al upstream or downstream of MYC, in addition to the apparent cluster region surrounding the ®rst exon (Joos et al., 1992; Axelson et al., 1994) . Alternatively, other oncogene(s) upstream of BCL6 may be deregulated by the translocation(s) or exert long-range in¯uence on BCL6 expression.
As previously noted in the other DLCLs, the BCL6 gene in all these cases studied exhibited mutations and/ or deletion in the region spanning the exon1-intron1 boundary. By RT ± PCR analysis of BCL6 expression in tumor 1254, we have shown that the allele with the deletion probably is silent, possibly due to loss of the preferred promoter (pb) 3' of the ®rst exon. The fact that the mutated allele appeared to be the only expressed allele in this translocation is consistent with the role of mutation in BCL6 activation. The mutation analysis of the three tumors with the t(2;3)(q21;q27) translocation reported here is also consistent with our previous observation that BCL6 mutation is independent of rearrangement by translocation. Figure 4 Mapping the 3q27-ABR breakpoint in tumor 1562. (a) Schematic representation of a 400 kb contig of P1, PAC, and YAC clones from the genomic region of 3q27. The positions of BCL6 and associated MBR are indicated. The ABR is located approximately 200 ± 270 kb 5' (telomeric) to the BCL6 gene as determined by a combination of PFGE and hybridization analysis (Butler et al., 1997) . The ends of P1, PAC, and YAC clones serve as markers of overlap between adjacent clones, and are named according to their clone of origin, followed by their primer derivation (T7 or SP6 for P1/PAC) or orientation (left (L) or right (R) for YAC). The point of overlap between clones is indicated by the vertical dashed lines on the map. Probe XN 1.3 was isolated from a genomic phage l-15-1952 contained within the ABR. (b). Southern blot showing rearrangement in tumor 1562 DNA using probe XN 1.2 from ABR. Arrowheads indicate the rearranged restriction fragments t(2;3)(q21;q27) translocation in NHL W Chen et al
Materials and methods
Tumor ascertainment and cytogenetics
Tumors 1187, 1254 and 1562 were part of a previously described ascertainment of NHL at the Memorial SloanKettering Cancer Center (MSKCC) (Ot et al., 1994) . The tumors were diagnosed based on histopathologic, immunophenotypic, and immunogenotypic analysis as described previously (Ot et al., 1994) . Cytogenetic analysis of disaggregated lymph node cells was performed following short-term culture, chromosome preparation, and Gbanding, according to conventional methods. Each tumor specimen revealed a t(2;3)(q21;q27) translocation. Case 1187 was a 54-year-old male with follicular small-cleaved cell lymphoma (FSCL) with the chromosomal complement: 48,XY, t(2;3)(q21;q27),i(6)(p10),+12,der (12) 710,716,+mar1,+mar2, +mar3[cp15] .
Fluorescence in situ hybridization (FISH) analysis of BCL6 genomic locus
The PAC clone 133M19 which covers the 100 kb upstream of BCL6 was labeled with biotin-14-dUTP by nick translation and hybridized to interphase nuclei from tumor cells. Hybridization signals were visualized with FITC-conjugated avidin (Oncor) following staining with propidium iodide.
Analysis of BCL6 rearrangements by Southern blotting and cloning of the rearranged bands
Genomic DNA from the the tumor biopsies and placental control DNAs were digested with the restriction enzymes
BamHI and XbaI, electrophoresed on a 0. 8% agarose gel, and transferred to a nylon membrane (Oncor). The blot was hybridized sequentially with the BCL6-MBR probes pGS4.0 (a 4 kb SacI fragment), pGRB5.1 (a 5.1 kb EcoRI/ BamHI fragment), and pGFB1.8 (a 1.8 kb BamHI fragment) (Figure 2a ). In the case of tumor 1562, DNA digested with HindIII and BamHI was also hybridized with the ABR probe XN 1.3. A genomic library of tumor 1254 was prepared by Sau3A partial digestion of DNA followed by ligation into lambda GEM-11 (Promega). The library was screened with the pGS4.0 probe. Positive clones were selected and mapped. Rearranged fragments were subcloned into pGEM-7Zf(7) (Promega) and sequenced.
Mutation analysis and expression of BCL6 alleles by RT ± PCR
Genomic DNAs isolated from tumors 1187, 1562, Lyl, a DLCL cell line (Tweeddale et al., 1987) (positive control) and placenta (negative control) were ampli®ed by PCR with primers spanning the ®rst exon and the 5' end of the ®rst intron as previously described (Migliazza et al., 1995) . SSCP analysis was performed according to described methods (Xu et al., 1994) . For 5' anchor RT ± PCR analysis, total RNA was isolated from a snap-frozen sample of tumor 1254 using the RNAgents reagent (Promega). 5'RACE analysis of the BCL6 transcripts was performed using the 5'RACE kit (GIBCO/BRL) following manufacturer's recommendations. The primers used for cDNA ampli®cation were as previously described (Ye et al., 1997) , except that the reverse primer 567 (AGGGTT-GATCTCAGGATC) at exon 4 was also used for the ®nal ampli®cation. The ®nal PCR product was subcloned into PGEM-T (Promega) and sequenced. Representative results from PCR products E1.11 and E1.14 at the exon-intron 1 boundary from tumors 1187 and 1562. Arrows point to bands representing conformation changes. DNA from placenta (N) and Ly1, a DLCL cell line previously documented to have a mutation (Migliazza et al., 1995) were used as negative and positive controls, respectively
Figure 6 BCL6 expression detected by 5' anchor RT ± PCR. The ®rst strand cDNA derived from patient 1254 was subjected to PCR ampli®cation with 5' anchor forward primer (GIBCO/BRL) and reverse primer 567. The fragment sizes of the marker fX174 RF DNA/HaeIII are indicated t(2;3)(q21;q27) translocation in NHL W Chen et al
